MYGN Myriad Genetics Inc.

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

News release updated to include the members of the management team speaking at the conference.

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam Raha, COO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET).

The presentation will be available through a live webcast in the investor relations section of Myriad’s website at . An archived edition of the presentation will be available later that day.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .

Investor Contact

Matt Scalo

(801) 584-3532

Media Contact

Glenn Farrell

(385) 318-3718



EN
08/01/2025

Underlying

MYGNMyriad Genetics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE
Free
MYGN Myriad Genetics...

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthc...

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference News release updated to include the members of the management team speaking at the conference. SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam Raha, COO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor relations section...

January 8, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Confe...

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor relations section of Myriad’s website at . An archived edition of the presentation will be available later that day. About Myriad GeneticsMyriad...

January 8, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

MD Anderson and Myriad Genetics form strategic alliance to evaluate cl...

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a po...

January 7, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibili...

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate Responsibility Report, highlighting key efforts that reflect its commitment to conduct operations as a responsible corporation in the healthcare industry. “Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics,” said Paul J. Diaz, President and CEO, Myriad Genetics. “In concert with our mission...

January 6, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant A...

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a study has been named in the American Journal of Human Genetics as one of its . The study was selected by the Genomic Medicine Working Group at the . The study by Mabey et a...

December 19, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch